HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
The ADC conjugation process involves linking the drug payload to the antibody via a linker at a defined drug-to-antibody ratio (DAR). The primary objective of process development is to design an efficient process flow, optimize conjugation reaction parameters, and purify the target product while minimizing product-related impurities (e.g. aggregates and fragments) and process-related impurities (e.g., residual free drug and solvents).
Dedicated Lab:
We have established a dedicated ADC laboratory equipped with a negative-pressure isolator and a biosafety cabinet, ensuring both operator safety and compound integrity during processing.
Experienced:
Our team has successfully developed lysine, cysteine, and enzyme-mediated conjugation processes. By leveraging our expertise in reaction chemistry, we use both OFAT and DOE studies to design optimized processes tailored to your specific needs and objectives.
CDMO@hjbbio.com
